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Introduction
Systemic lupus erythematosus (SLE) is the prototypic 
chronic inﬂ  ammatory systemic autoimmune disease, but 
many aspects of its pathogenesis remain poorly under-
stood. As described in the following sections, the recent 
report from Suh and colleagues [1] may help us to inte-
grate an understanding of how innate immune pathways 
aﬀ  ect autoimmune pathogenesis.
One of the most fundamental challenges to the immune 
system is the eﬃ   cient recognition and clearance of the 
body’s own cells when senescence, injury or other causes 
lead to their entry into programmed death pathways, 
which are a normal outcome of cell and tissue turnover. 
Apoptotic cell (AC) clearance is therefore important for 
resolving the cellular consequences of normal 
development during embryogenesis, and for cellular 
proliferation and diﬀ  erentiation that continues through-
out life.
Th  e homeostatic pathways that regulate apoptotic 
clearance are also involved in the resolution of inﬂ  am  ma-
tion. Yet inﬂ  ammation is a beneﬁ  cial host response to 
foreign challenge or tissue injury, representing a tightly 
choreographed sequence of changes in tissue and blood 
factors and cellular recruitment and subsequent clear-
ance that ultimately restores tissue structure and func-
tion. Both exposure to ACs and the clearance of ACs have 
been recognized as important mechanisms for the 
resolution of inﬂ  ammation in vivo (reviewed in [2]), while 
an inability to control inﬂ  ammatory responses is at the 
root of many chronic diseases.
Conditions associated with defects in phagocytic 
clearance of dead and dying host cells, and especially C1q 
and IgM deﬁ  ciency states, may lead to lupus-like disease 
[2]. Th   ese associated clearance defects may also result in 
cellular progression to secondary necrosis and the release 
of self-ligands (such as High-mobility group protein B1 
(HMGB-1) and heat shock protein (HSP)) for inﬂ  am-
matory innate receptors and of self-antigens that drive 
stimulation and selection of autoreactive lymphocytes.
The TAM family and the GAS6 and Protein S ligands
Discovered in 1991, the TAM family of receptor tyrosine 
kinases (RTKs) may be amongst the most recent class of 
protein phosphatases to appear in evolution (reviewed in 
[3]). Th  e three family members, TYRO3 (also termed 
SKY, BRT, ETK, TIF, DTK, and RSE), the prototypic 
member AXL (ARK, UFO, and TYRO7), and MERTK 
(c-EYK, NYK, and TYRO12), share a conserved structure 
of two immunoglobulin-like motifs and two ﬁ  bronectin 
type III  repeats in the extracellular domain, and a 
cytoplasmic domain with a conserved catalytic kinase 
region. TAM members play fundamental roles in diverse 
cell functions of proliferation, diﬀ  erentiation,  survival, 
migra  tion, and metabolism, and are variably expressed in 
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members are also prominently expressed in the immune 
system, especially in professional phagocytic cells, 
macro  phages (Mφs) and dendritic cells (DCs).
Ligand interactions are essential for TAM triggering. 
Best studied is the product of growth-arrest-speciﬁ  c gene 
6 (GAS6), a vitamin K-dependent protein widely secreted 
by most tissues [4]. GAS6 can bind and activate all three 
receptors via tyrosine autophosphorylation but with 
markedly diﬀ  erent aﬃ   nities (AXL ≥ TYRO3 >> MER) [4]. 
GAS6 may be primarily locally produced in tissues, with 
only limited levels in the circulation. Many cells express 
GAS6, which may provide autocrine functions for TAM 
triggering, and levels can increase during apoptosis death 
or in an inﬂ  ammatory milieu [5].
Th   e second ligand for the TAM system, Protein S, shares 
domain organization and approximately 44% sequence 
identity with GAS6. Both GAS6 and Protein S include a 
speciﬁ   c GLA domain that undergoes post-translational 
modiﬁ   cation by vitamin K-dependent gamma-carboxy-
lation to provide positively charged residues for binding of 
phosphatidylserine residues exposed on ACs [3]. Th  rough 
GLA domains, GAS6 and Protein S serve as bridging 
molecules to TAM receptors on Mφs and DCs [6], 
enhancing AC uptake and engulfment [5].
Protein S is also a negative regulator of blood coagu-
lation as it is a cofactor for activated Protein C-mediated 
inactivation of factors Va and VIIIa, which may suggest 
there are interconnections between the TAM system and 
anti-phospholipid syndrome. Th  e speciﬁ   cities of these 
two ligands diﬀ  er; Protein S was reported to be a speciﬁ  c 
agonist for TYRO3, while in cells that co-express TYRO3, 
Protein S is also a potent MERTK agonist [7]. Protein S is 
produced and secreted in liver and approximately 60% of 
circulating Protein S is in complex with C4-binding 
protein. None  theless, circulating levels are still 1,000-fold 
higher than those of GAS6, with great variation even 
amongst healthy individuals.
TAM dysregulation and systemic autoimmunity
In murine systems, the most serious consequences of 
mutations of the TAM genes involve the immune system. 
TAM-deﬁ  cient mice have severe defects in AC clearance, 
impaired control of inﬂ  ammatory responses, and develop 
frank autoimmune disease associated with sustained 
antigen presenting cell activation [8-11]. Th  is likely 
results from the loss of TAM regulation of two related 
phenomena: the phagocytosis of ACs by Mφs and DCs, 
and control of innate inﬂ  ammatory response to patho-
gens and self-ligands.
TAM receptor interactions may lead to downstream 
inhibition of the mitogen-activated protein kinase and 
NF-κB cascades, which dominate inﬂ  ammatory signaling 
[5,6,10]. However, there remain controversies regarding 
down  stream TAM signaling events, and diﬀ  erent 
pathways may also be triggered in diﬀ  erent cell types. 
Notably, in murine FLT3-L generated DCs, inhibition of 
inﬂ   amma  tory signaling has been reported to be 
dependent on SOCS (Suppressor of cytokine signaling) 
[10].
Low plasma Protein S but not GAS6 levels correlate 
with SLE disease activity
Suh and colleagues [1] reported results from surveys of 
serum GAS6 and Protein S levels in well-characterized 
SLE patients. Th   ey found that free Protein S levels were 
highly directly correlated with C3 and C4 levels, and that 
free Protein S levels were lower in SLE patients with a 
history of serositis, neurologic disorder, hematologic dis-
order and immunologic disorder. Levels of Protein S were 
also lower in patients with anti-cardiolipin antibodies, 
although there was no correlation with lupus anti-
coagulant or anti-β2 glycoprotein I antibody. Overall, 
there were no signiﬁ  cant diﬀ  erences between levels in 
SLE patients and healthy adults, and there was also no 
relationship between GAS6 and Protein S levels within 
individual SLE patients. Findings for GAS6 levels were 
limited to evidence of elevation in patients with a history 
of neurologic involvement.
Conclusion
Th  e studies from Cohen and coworkers [1] highlight a 
new perspective on how breaches in regulatory control of 
a fundamental homeostatic anti-inﬂ  ammatory pathway, 
which ﬁ   rst arose far before the mammalian adaptive 
immune system, may be a major determinant of SLE 
clinical manifestations and/or local activity. It may not be 
surprising that the involvement of some but not all organ 
systems was associated with lower free Protein S levels, 
as the contributions of inﬁ  ltrating Mφ and DCs, or other 
pathways aﬀ  ected by the TAM system, may vary greatly 
in diﬀ  erent  aﬀ   ected anatomic sites. Th  is likely also 
explains why there was no signiﬁ  cant correlation with the 
Systemic Lupus Erythematosus Disease Activity Index 
(SLEDAI) or the British Isles Lupus Assessment Group 
(BILAG) disease index [1].
Th  e study did not examine the functional roles of 
Protein S and GAS6 in human disease, and also did not 
evaluate for ﬂ  uctuations over time in an individual or 
with regard to changes in disease activity. Th  erefore, it 
remains to be determined whether changes in free 
Protein S levels primarily reﬂ  ect diﬀ  erences in systemic 
production, or rates of consumption at inﬂ  ammatory 
sites or via other degradation pathways, or rates of 
recruitment by activated Protein C in the micro  vascu-
lature. Th  e current ﬁ   ndings therefore underscore the 
need for further investigation of how Protein S may 
directly (or indirectly) aﬀ  ect lupus pathogenesis.
Silverman Arthritis Research & Therapy 2010, 12:144 
http://arthritis-research.com/content/12/5/144
Page 2 of 3Abbreviations
A, apoptotic cell; DC, dendritic cell; GAS6, Growth-arrest-specifi  c gene 
6; Mφ, macrophage; RTK, receptor tyrosine kinase; SLE, systemic lupus 
erythematosus.
Competing interests
The author declares that he has no competing interests.
Acknowledgements
Financial support: grants from the NIH; R01 AI068063 and ARRA supplement, 
R01AI090118, and from the ACR REF Within Our Reach campaign, the Alliance 
for Lupus Research and the Arthritis Foundation.
Published: 27 October 2010
References
1.  S  uh CH, Hilliard BA, Li S, Merrill JT, Cohen PL: TAM receptor ligands in lupus: 
Protein S but not Gas6 levels refl  ect disease activity in systemic lupus 
erythematosus. Arthritis Res Ther 2010, 12:R146.
2.  Savill J, Fadok V: Corpse clearance defi  nes the meaning of cell death. Nature 
2000, 407:784-788.
3.  Lemke G, Rothlin CV: Immunobiology of the TAM receptors. Nat Rev 
Immunol 2008, 8:327-336.
4.  Crosier KE, Crosier PS: New insights into the control of cell growth; the role 
of the AxI family. Pathology 1997, 29:131-135.
5.  Sen P, Wallet MA, Yi Z, Huang Y, Henderson M, Mathews CE, Earp HS, 
Matsushima G, Baldwin AS Jr, Tisch RM: Apoptotic cells induce Mer tyrosine 
kinase-dependent blockade of NF-kappaB activation in dendritic cells. 
Blood 2007, 109:653-660.
6.  Seitz HM, Camenisch TD, Lemke G, Earp HS, Matsushima GK: Macrophages 
and dendritic cells use diff  erent Axl/Mertk/Tyro3 receptors in clearance of 
apoptotic cells. J Immunol 2007, 178:5635-5642.
7.  Prasad D, Rothlin CV, Burrola P, Burstyn-Cohen T, Lu Q, Garcia de Frutos P, 
Lemke G: TAM receptor function in the retinal pigment epithelium. Mol Cell 
Neurosci 2006, 33:96-108.
8.  Lu Q, Lemke G: Homeostatic regulation of the immune system by receptor 
tyrosine kinases of the Tyro 3 family. Science 2001, 293:306-311.
9.  Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, Roubey RA, 
Earp HS, Matsushima, G, Reap EA: Delayed apoptotic cell clearance and 
lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine 
kinase. J Exp Med 2002, 196:135-140.
10.  Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G: TAM receptors are 
pleiotropic inhibitors of the innate immune response. Cell 2007, 
131:1124-1136.
11.  Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, Cohen PL, Earp HS, 
Matsushima GK: Phagocytosis and clearance of apoptotic cells is mediated 
by MER. Nature 2001, 411:207-211.
doi:10.1186/ar3162
Cite this article as: Silverman GJ: Rethinking the red wolf disease: does 
Protein S suppress systemic lupus erythematosus clinical activity? Arthritis 
Research & Therapy 2010, 12:144.
Silverman Arthritis Research & Therapy 2010, 12:144 
http://arthritis-research.com/content/12/5/144
Page 3 of 3